Vilya
de novo drug design inspired by nature & AI
Seattle, United States · Founded 2022 · $71.0M raised
- Headquarters
- Seattle, Washington
- Employees
- 11–50
- Founded
- 2022
- Business Model
- B2B
- Website
- vilyatx.com
- Total Funding
- $71.0M
- Last Round
- $21.0M Series AJun 2024
- Rounds
- 2
About
Computational biotechnology company designing de novo macrocycles with AI for therapeutic drug discovery.
Summary
Vilya is an Artificial Intelligence company based in Seattle, United States, founded in 2022. It has raised $71.0M in total across 2 rounds, most recently a $21.0M Series A round in Jun 2024. Investors include ARCH Venture Partners, Menlo Ventures and Madrona Venture.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...